jCyte, Inc.

The future of ophthalmology is here! Our recent panel was a unique and thrilling one featuring the foremost experts in genetic engineering and cell transportation. Attendees were captivated by the cutting-edge technologies revolutionizing the field and gained unparalleled insights into the industry's direction. Marjan Farid, MD, and Baruch D. Kuppermann, MD, PhD, masterfully moderated this stellar lineup, ensuring an engaging and dynamic discussion. Greg Kunst, CEO, Aurion Biotech: Unveiled a revolutionary paradigm shift in treating corneal blindness with a minimally invasive solution that transforms one donor cornea into 1000 doses, making treatment more accessible and economically viable. Celebrated the success of phase 1-2 trials and breakthrough therapy designation. John Pollack, MD, CMO, jCyte, Inc.: Introduced Famzeretzel, a groundbreaking living factory of neurotrophic factors, and highlighted why ophthalmology is the perfect field for cell therapy, thanks to its minimally invasive procedures and diverse cell types. Rich Small, CEO, Neurotech Pharmaceuticals, Inc.: Shared exciting news about the FDA's priority review of NT-501 for MacTel, emphasizing its cutting-edge encapsulated cell technology and long-term cell health, with impressive results in reducing EZ area loss. Jeffrey Goldberg, MD, PhD, Co-founder, Emmecell: Showcased innovative magnetic cell delivery methods aimed at restoring vision, with promising developments in treating geographic atrophy and exciting phase 1 trial outcomes. This one-of-a-kind panel provided invaluable insights, positioning attendees at the forefront of ophthalmic innovation. Stay tuned for more groundbreaking updates on our LinkedIn feed as we continue to push the boundaries of eye care throughout the day! #OTF2024 #GeneticEngineering #CellTransplantation

🌟 Can’t make it to RWC 2024? No worries! 🌐 Join us virtually and catch select live presentations on Facebook Live. Stay connected with the latest in retina innovation from wherever you are. Tune in at Retina World Congress on Facebook 📲 #RWC2024 #RetinaInnovation #FacebookLive

Join us on Saturday, May 4th at the Four Seasons Hotel Seattle for the "𝗦𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁 𝗼𝗻 𝗥𝗲𝗴𝗲𝗻𝗲𝗿𝗮𝘁𝗶𝘃𝗲 𝗠𝗲𝗱𝗶𝗰𝗶𝗻𝗲" moderated by world-renowned expert Dr. Mark Humayun. This session will delve into groundbreaking advancements and innovative approaches in vision restoration with highly esteemed speakers Sulagna Bhattacharya, Peter Francis, MD PhD, Ram Palanki, John Pollack, MD, and Matthias Steger PhD, MBA. Don't miss your chance to gain strategic insights and network with key players in the field. https://lnkd.in/geVddkw4 USC Roski Eye Institute Nanoscope Therapeutics Inc. Ray Therapeutics, Inc. REGENXBIO Inc. jCyte, Inc. Endogena Therapeutics, Inc. #OIS #OISRetina #OISRetina2024 #Ophthalmology #Innovation #RoskiEyeInstitute #Nanoscope #RayTherapeutics #REGENXBIO #jCyte #Endogena #SulagnaBhattacharya #PeterFrancis #RamPalanki #JohnPollack #MatthiasSteger

Over the past few weeks, Elixir Associates have had the pleasure of partnering with jCyte, Inc. & helping them successfully hire their new Senior Director of Clinical Operations (Angeline Lo). 👁 👁 👁 We are immensely proud to have worked with three outstanding leaders within the business - Rob Beathard, CPA (Chief Strategy Officer), John Pollack, MD (Chief Medical Officer) & Adrian Morris (Chief Development Officer). 🙌 jCyte, Inc. is pursuing multiple drug development programs for a range of degenerative retinal disorders and optic nerve conditions, focusing on preserving and restoring vision in patients. 👀 #Partnership #ElixirAssociates #Hiring #jCyte #Leaders #ClinicalOperations #ClinicalResearch #ClinicalDevelopment #LifeSciences #Pharma #Eye #Retinal #Biotechnology #Opthalmology #DrugDevelopment